Semaglutide is the compound that turned “GLP-1” into a household word. It is behind Ozempic, Wegovy, and Rybelsus, and it changed how doctors treat both diabetes and obesity. It is also the one compound in this deep-dive batch where the evidence is not thin. It is deep, human, and approved. That changes the whole tone of this page.
One thing to get straight up front. The approved drug and the gray-market “research” semaglutide sold in vials online are not the same thing. The approved product is what the trials below studied. The vial from a research-chemical site is unapproved, often mislabeled, and legally a different animal. Keep that split in mind.
Strong. This is a fully FDA-approved drug with large, randomized, placebo-controlled human trials behind every major claim. When we say semaglutide lowers weight, cuts heart risk, and protects kidneys, those come from trials with tens of thousands of people, not from animal studies or anecdote. That is rare in the peptide world and worth saying plainly.
Semaglutide is a GLP-1 receptor agonist. GLP-1 is a natural gut hormone your body releases after you eat. Semaglutide is a modified copy of it, engineered in three ways so it resists breakdown and binds to albumin in your blood. That gives it a half-life of about a week, which is why it is a once-weekly shot. There is also a daily oral tablet, Rybelsus.
Same molecule, three brands. Ozempic for diabetes. Wegovy for weight management. Rybelsus is the oral form for diabetes.
The story runs through an unlikely source. In 1991, a researcher isolated a GLP-1-like compound from Gila monster venom that was far more stable than the human hormone. That led to the first GLP-1 drugs. Novo Nordisk then built a platform of fatty-acid-modified GLP-1 analogs, first liraglutide (daily), then semaglutide (weekly). Ozempic was approved in 2017, Rybelsus in 2019, and Wegovy in 2021.
Semaglutide acts on the GLP-1 receptor in several places. In the pancreas it boosts insulin release, but only when blood sugar is high, which is why on its own it rarely causes low blood sugar. It lowers glucagon, which reduces the sugar your liver dumps out. It slows how fast your stomach empties, so you feel full longer. And it acts in the brain’s appetite centers, which is what people mean when they describe reduced “food noise.”
This is where semaglutide stands apart, so here are the real numbers.
The approved uses are type 2 diabetes, chronic weight management, cardiovascular risk reduction in the right patients, kidney protection in diabetes, and now MASH. Off-label and gray-market use is overwhelmingly for weight loss.
The most common side effects are gastrointestinal. Nausea, vomiting, diarrhea, and constipation, worst while the dose is going up, and the main reason people quit. Most ease with time.
Less common but serious: gallbladder disease, pancreatitis, and gastroparesis, which is severe slowing of the stomach. There is a boxed warning for thyroid C-cell tumors based on rodent studies, and it is contraindicated if you have a personal or family history of medullary thyroid cancer or the MEN2 syndrome. Some weight lost is muscle, so resistance training and protein matter. “Ozempic face” is just facial fat loss from rapid weight loss, not a specific toxicity.
Two things worth clearing up. The suicidality worry was investigated by both the FDA and European regulators, and neither found a causal link, with some data actually suggesting lower risk. And because it slows stomach emptying, tell your anesthesia team before any surgery. Guidance has shifted toward individualized precautions rather than automatically stopping it.
Because this is an approved drug, the dosing is public labeling, so here it is as fact. Ozempic starts at 0.25 mg weekly for four weeks, which is a starter dose, not a treatment dose, then steps up to 0.5, 1, and a max of 2 mg. Wegovy titrates over about 16 weeks up to 2.4 mg weekly. Rybelsus is a daily tablet at 3, 7, or 14 mg, taken on an empty stomach.
The gray-market angle is the caution. “Research” semaglutide is not the approved product, dosing errors from multidose vials have sent people to the hospital, and the FDA is actively winding down compounded versions. This site does not give injection instructions, and the approved product is prescribed and titrated by a clinician for a reason.
Semaglutide is a fully FDA-approved prescription drug across the indications above. The compounding pathway has closed. The FDA declared the shortage over in early 2025, ended the enforcement grace period for pharmacies, and in 2026 moved to keep semaglutide permanently off the list that would allow bulk compounding. So the compounded and “research” versions that filled the shortage are being shut down.
The natural comparison. Semaglutide hits one receptor. Tirzepatide hits two. In the head-to-head SURMOUNT-5 trial, tirzepatide produced more weight loss, about 20% versus about 14%. Semaglutide still has the larger cardiovascular outcome record and the kidney and liver approvals. Both are effective. Tirzepatide currently edges weight loss.
Is semaglutide the same as Ozempic? Semaglutide is the drug. Ozempic, Wegovy, and Rybelsus are brands of it with different doses and approved uses.
How much weight do people lose? About 15% on average over 68 weeks with the 2.4 mg injection, and about 16.6% with the oral 25 mg version. Individual results vary.
What happens if you stop? Weight tends to come back. It is used as long-term therapy.
Does it cause thyroid cancer? Rodent studies showed C-cell tumors and human relevance is unknown. It is contraindicated with a personal or family history of medullary thyroid cancer or MEN2.
Is the suicidality risk real? FDA and European reviews found no causal link, and some data suggest lower risk.
Is “research” semaglutide the same as Ozempic? No. It is unapproved, often mislabeled, and the FDA is ending legal compounding of it.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.